Toward a human papillomavirus vaccine.
Much progress has been made over the past 10 years with regard to development of a vaccine active against HPV. Successful protection has been achieved in animal models using species-specific papillomaviruses; however, HPV diversity may delay the development of successful HPV vaccines, especially those designed as therapeutic vaccines for the treatment of HPV-induced carcinoma and high-grade dysplasia of the cervix. Difficulties arise with regard to assessment of efficacy of potential vaccines. The impetus for long-term studies on vaccine efficacy will initially stem from in vitro evidence of responsiveness to the vaccine. The time when a vaccine will have an impact on the prevalence of high-grade dysplasia and invasive cancer is still some way off.
Rowen
D
D
Department of Genito-Urinary Medicine, Royal South Hants Hospital, Southampton, United Kingdom. DRowen1@compuserve.com
Lacey
C
C
D000818:Animals; D002294:Carcinoma, Squamous Cell / Q000517:prevention & control / Q000628:therapy / Q000821:virology; D003218:Condylomata Acuminata / Q000517:prevention & control / Q000628:therapy / Q000821:virology; D004195:Disease Models, Animal; D005260:Female; D016679:Genome, Viral; D006801:Humans; D007115:Immunization Schedule; D008297:Male; D027383:Papillomaviridae / Q000235:genetics / Q000276:immunology*; D030361:Papillomavirus Infections / Q000517:prevention & control* / Q000628:therapy; D053918:Papillomavirus Vaccines; D011230:Precancerous Conditions / Q000517:prevention & control / Q000628:therapy / Q000821:virology; D014412:Tumor Virus Infections / Q000517:prevention & control* / Q000628:therapy; D002578:Uterine Cervical Dysplasia / Q000517:prevention & control / Q000628:therapy / Q000821:virology; D014611:Vaccination; D014764:Viral Proteins / Q000235:genetics; D014765:Viral Vaccines
D053918:Papillomavirus Vaccines; D014764:Viral Proteins; D014765:Viral Vaccines